Jonathan Gardner

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.

A combination of AstraZeneca's Tagrisso and Hutchmed's Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight started seeking a partner for its autism drug.

The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

Adobe Advertising integrates cross-border measurement capability enabling advertisers to serve campaigns in one country and verify in-person visits

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.